Accelerated Medical Diagnostics, Inc., is a cancer diagnostics company bringing together expertise in cancer biology, chemotherapy drugs and diagnostics to develop objective, reproducible tests designed to provide clinicians with information to enhance patient care. Early in the field of predictive chemotherapy diagnostics, the firm is stucrured around developing clinically validated tests that empower clinicians better to tailor care to each individual patient. In collaborations with university hospitals - UC Davis and UCSF - Accelerated Medical Diagnostics is currently conducting a retrospective clinical trial. The firm is strategically focused on induction chemotherapy for acute myeloid leukemia (AML) and close to commercialization of the firm's test - InductDx - that enables measurement of cellular responses to nontoxic “microdoses” of chemotherapy administered to cells derived from patient blood samples.
